Topline data were announced from a phase 3 trial evaluating zanzalintinib in combination with atezolizumab in patients with previously treated non-microsatellite instability (MSI)-high metastatic ...

Our trial provides proof of concept that cytokine-armored CAR T-cell treatment is feasible and may enhance antitumor activity without additional toxic effects,” researchers reported.

The survey was conducted in May 2025 online (978 participants) and by telephone (30 participants).

A review of the literature revealed that immune effector cell-associated neurotoxicity syndrome (ICANS) is a common adverse effect of CAR-T therapy.

Relacorilant plus nab-paclitaxel could be a new standard of care for platinum-resistant ovarian cancer, according to Alexander Olawaiye, MD.

HealthDay News — Race definitions have limited impact on cancer rates for Whites, Blacks, and Asians, but do impact rates in multiracial individuals, according to a study published online July 21 in ...

Venetoclax-based regimens showed a trend toward improved survival compared to BTK inhibitors, although subgroup sizes were small.

Adding an immune checkpoint inhibitor to neoadjuvant chemotherapy can improve pathologic complete response rates and may improve survival in patients with muscle-invasive bladder cancer, research ...

In patients with multiple myeloma (MM), serum concentration of chitinase 3-like protein-1 (CHI3L1) protein is correlated with disease severity and predicts disease progression, according to research ...

Researchers sought to improve HBOC genetic testing in underserved areas through cancer risk assessment at mammography.

Launch prices for self-administered targeted anticancer therapies have grown precipitously,” researchers wrote.

US researchers analyzed national death certificate data to compare trends in hepatocellular carcinoma (HCC)-related mortality and underlying etiologies of chronic liver disease linked to HCC-related ...